DOI QR코드

DOI QR Code

High Lipoprotein(a) Levels are Associated With Long-Term Adverse Outcomes in Acute Myocardial Infarction Patients in High Killip Classes

  • Cho, Jae-Yeong (Heart Research Center of Chonnam National University Hospital, Cardiovascular Research Institute of Chonnam National University) ;
  • Jeong, Myung-Ho (Heart Research Center of Chonnam National University Hospital, Cardiovascular Research Institute of Chonnam National University) ;
  • Ahn, Young-Keun (Heart Research Center of Chonnam National University Hospital, Cardiovascular Research Institute of Chonnam National University) ;
  • Hong, Young-Joon (Heart Research Center of Chonnam National University Hospital, Cardiovascular Research Institute of Chonnam National University) ;
  • Park, Hyung-Wook (Heart Research Center of Chonnam National University Hospital, Cardiovascular Research Institute of Chonnam National University) ;
  • Yoon, Nam-Sik (Heart Research Center of Chonnam National University Hospital, Cardiovascular Research Institute of Chonnam National University) ;
  • Yoon, Hyun-Ju (Heart Research Center of Chonnam National University Hospital, Cardiovascular Research Institute of Chonnam National University) ;
  • Kim, Kye-Hun (Heart Research Center of Chonnam National University Hospital, Cardiovascular Research Institute of Chonnam National University) ;
  • Kim, Ju-Han (Heart Research Center of Chonnam National University Hospital, Cardiovascular Research Institute of Chonnam National University) ;
  • Cho, Jeong-Gwan (Heart Research Center of Chonnam National University Hospital, Cardiovascular Research Institute of Chonnam National University) ;
  • Park, Jong-Chun (Heart Research Center of Chonnam National University Hospital, Cardiovascular Research Institute of Chonnam National University) ;
  • Kang, Jung-Chaee (Heart Research Center of Chonnam National University Hospital, Cardiovascular Research Institute of Chonnam National University)
  • Received : 2010.02.13
  • Accepted : 2010.04.21
  • Published : 2010.10.30

Abstract

Background and Objectives: An elevated concentration of lipoprotein(a) {Lp(a)} is associated with an increased prevalence and increased severity of coronary artery disease. However, the relationship between Lp(a) levels and outcomes after acute myocardial infarction (AMI) is unclear. Subjects and Methods: Between October 2005 and June 2007, we measured serum Lp(a) levels in 832 consecutive AMI patients (age, 62.8${\pm}$12.4 years, 600 men) on admission. They were divided into tertiles according to their serum Lp(a) levels {Tertile 1 (n=276), Lp(a)<13.8 mg/dL; Tertile 2 (n=279), Lp(a)=13.8-30.6 mg/dL; Tertile 3 (n=277), Lp(a)>30.6 mg/dL}. Results: There were no differences in baseline clinical characteristics among Tertiles 1, 2, and 3, except for proportions of Killip class III-IV patients (5.8% vs. 10.0% vs. 18.8%, respectively, p<0.001). There were significant differences in left ventricular ejection fractions (57.3${\pm}$11.4% vs. 55.9${\pm}$12.3% vs. 53.1${\pm}$13.1%, p<0.001). Among the laboratory findings, there were significant differences in total cholesterol (173.3${\pm}$37.2 vs. 183.5${\pm}$38.9 vs. 185.3${\pm}$43.8 mg/dL, p=0.001), low density lipoprotein-cholesterol (111.3${\pm}$34.3 vs. 122.9${\pm}$34.7 vs. 123.3${\pm}$39.4 mg/dL, p<0.001), apolipoprotein B (92.8${\pm}$25.4 vs. 100.8${\pm}$26.0 vs. 101.9${\pm}$28.8 mg/dL, p<0.001), and amino-terminal pro-brain natriuretic peptide levels (1805.2${\pm}$ 4343.3 vs. 2607.9${\pm}$5216.3 vs. 3981.5${\pm}$7689.7 pg/mL, p<0.001). After adjusting for multiple variables in the high Killip class (III-IV) subgroup, the risk estimate for major adverse cardiovascular events (MACE) at 1-year follow-up was significantly higher in Tertile 3 than in Tertiles 1 or 2 (hazard ratio 6.723, 95% confidence interval 1.037-43.593, p=0.046). Conclusion: In patients in high Killip classes, high serum levels of Lp(a) were significantly associated with long-term adverse outcomes after AMI.

Keywords

References

  1. Lee CK. Lipoprotein(a), Lp(a). Korean Circ J 1993;23:631-3. https://doi.org/10.4070/kcj.1993.23.5.631
  2. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein (a) modulation of endothelial surface fibrinolysis and its potential role in atherosclerosis. Nature 1989;339:303-5. https://doi.org/10.1038/339303a0
  3. Harpel PC, Gordon BR, Parker TS. Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. Proc Natl Acd Sci U S A 1989;86:3847-51. https://doi.org/10.1073/pnas.86.10.3847
  4. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein (a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acd Sci U S A 1992;89:10193-7. https://doi.org/10.1073/pnas.89.21.10193
  5. Park SH, Shin GJ. Lipoprotein (a) as a risk factor for coronary heart disease: whether related with NIDDM or not. Korean Circ J 1996;26:507-13. https://doi.org/10.4070/kcj.1996.26.2.507
  6. Jurgens G, Taddei-Peters WC, Koltringer P, et al. Lipoprotein (a) serum concentration and apolipoprotein (a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke 1995;26:1841-8. https://doi.org/10.1161/01.STR.26.10.1841
  7. Danesh J, Collins R, Peto R. Lipoprotein (a) and coronary heart disease: meta-analysis of prospective studies. Circulation 2000;102:1082-5. https://doi.org/10.1161/01.CIR.102.10.1082
  8. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein (a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 2008;117:176-84. https://doi.org/10.1161/CIRCULATIONAHA.107.715698
  9. Foody JM, Milberg JA, Pearce GL, Sprecher DL. Lipoprotein (a) associated with coronary artery disease in older women: age and gender analysis. Atherosclerosis 2000;153:445-51. https://doi.org/10.1016/S0021-9150(00)00427-5
  10. Jenner JL, Ordovas JM, Lamonfava S, et al. Effects of age, sex, and menopausal status on plasma lipoprotein (A) levels: the Framingham Offspring Study. Circulation 1993;87:1135-41. https://doi.org/10.1161/01.CIR.87.4.1135
  11. Seman LJ, Breckenridge WC. Isolation and partial characterization of apolipoprotein (a) from human lipoprotein (a). Biochem Cell Biol 1986;64:999-1009. https://doi.org/10.1139/o86-133
  12. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipemic subjects treated with nicotinic-acid. J Intern Med 1989;226:271-6. https://doi.org/10.1111/j.1365-2796.1989.tb01393.x
  13. Morishita R, Ishii J, Kusumi Y, et al. Association of serum oxidized lipoprotein (a) concentration with coronary artery disease: potential role of oxidized lipoprotein (a) in the vascular wall. J Atheroscler Thromb 2009;16:410-8. https://doi.org/10.5551/jat.No224
  14. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 1989;80:1313-9. https://doi.org/10.1161/01.CIR.80.5.1313
  15. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein (a) and Cardiovascular Disease: recent advances and future directions. Clin Chem 2003;49:1785-96. https://doi.org/10.1373/clinchem.2003.023689
  16. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein (a). JAMA 1995;274:1771-4. https://doi.org/10.1001/jama.274.22.1771
  17. Insull W Jr, McGovern ME, Schrott H, et al. Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. Arch Intern Med 2004;164:1121-7. https://doi.org/10.1001/archinte.164.10.1121
  18. Merki E, Graham MJ, Mullick AE, et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein (a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein (a) transgenic mice. Circulation 2008;118:743-53. https://doi.org/10.1161/CIRCULATIONAHA.108.786822
  19. Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006;114:1729-35. https://doi.org/10.1161/CIRCULATIONAHA.105.606442
  20. Hearn JA, Donohue BC, Baalbaki H, et al. Usefulness of serum lipoprotein (a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1992;69:736-9. https://doi.org/10.1016/0002-9149(92)90497-M
  21. Desmarais RL, Sarembock IJ, Ayers CR, Velmon SM, Powers ER, Gimple LW. Elevated serum lipoprotein (a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation 1995;91:1403-9. https://doi.org/10.1161/01.CIR.91.5.1403
  22. Ribichini F, Steffenino G, Dellavalle A, et al. Plasma lipoprotein (a) is not a predictor for restenosis after elective high-pressure coronary stenting. Circulation 1998;98:1172-7. https://doi.org/10.1161/01.CIR.98.12.1172
  23. Rhew JY, Jeong MH, Hong YJ, et al. The effects of lipoprotein (a) on coronary stent restenosis. Korean Circ J 2001;31:476-83. https://doi.org/10.4070/kcj.2001.31.5.476
  24. Hoffmann R, Minz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis: a serial intravascular ultrasound study. Circulation 1996;94:1247-54. https://doi.org/10.1161/01.CIR.94.6.1247
  25. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein (a). Science 1993;260:1655-8. https://doi.org/10.1126/science.8503012
  26. Morita Y, Himeno H, Yakuwa H, Usui T. Serum lipoprotein (a) level and clinical coronary tenosis progression in patients with myocardial infarction: re-revascularization rate is high in patients with high-Lp(a). Circ J 2006;70:156-62. https://doi.org/10.1253/circj.70.156
  27. Sim DS, Kim JH, Jeong MH. Differences in clinical outcomes between patients with ST-elevation versus non-ST-elevation acute myocardial infarction in Korea. Korean Circ J 2009;39:297-303. https://doi.org/10.4070/kcj.2009.39.8.297
  28. Marcovina SM, Albers JJ, Scanu AM, et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein (a). Clin Chem 2000;46:1956-67.
  29. Kim CJ, Kwak MH, Kim KM, Ryu WS, Park JT, Ryoo UH. Lipoprotein (a) as an acute phase reactant. Korean J Lipidol 1996;6:111-5.
  30. Heinemann K, Rubig A, Strothmann A, Nahum GG, Heinemann LA. Prevalence and opinions of hormone therapy prior to the Women's Health Initiative: a multinational survey on four continents. J Womens Health 2008;17:1151-66. https://doi.org/10.1089/jwh.2007.0584

Cited by

  1. Comparison of Clinical Outcomes between ST-Segment Elevation Myocardial Infarction and Non-ST-Segment Elevation Myocardial Infarction in Patients Younger Than 40 Years Who Underwent Percutaneous Coron vol.82, pp.2, 2010, https://doi.org/10.3904/kjm.2012.82.2.175
  2. Electrical and Optical Properties of ZnO:Ag Thin-Films Depend on Lamination Formation by DC Magnetron Sputtering vol.1110, pp.None, 2015, https://doi.org/10.4028/www.scientific.net/amr.1110.211
  3. The relationship between Lp(a) and CVD outcomes: a systematic review vol.15, pp.None, 2016, https://doi.org/10.1186/s12944-016-0258-8
  4. Association of lipoprotein(a) with long‐term mortality following coronary angiography or percutaneous coronary intervention vol.40, pp.9, 2010, https://doi.org/10.1002/clc.22712
  5. South Asian Cardiovascular Disease & Cancer Risk: Genetics & Pathophysiology vol.43, pp.6, 2010, https://doi.org/10.1007/s10900-018-0527-8
  6. Prognostic value of lipoprotein (a) level in patients with coronary artery disease: a meta-analysis vol.18, pp.1, 2010, https://doi.org/10.1186/s12944-019-1092-6
  7. Lipoprotein(a) as a marker for predicting coronary collateral circulation in patients with acute myocardial infarction vol.17, pp.1, 2020, https://doi.org/10.2217/pme-2018-0127
  8. Prognostic Value of Lipoprotein(a) Levels in Patients Undergoing Coronary Angiography for Premature Acute Coronary Syndromes vol.71, pp.2, 2010, https://doi.org/10.1177/0003319719886493